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Abstract 
Background: The need for a highly efficacious vaccine against Plasmodium 
falciparum remains pressing. In this controlled human malaria infection (CHMI) 
study, we assessed the safety, efficacy and immunogenicity of a schedule combining 
two distinct vaccine types in a staggered immunization regimen: one inducing high-
titer antibodies to CSP (RTS,S/AS01B) and the other inducing potent T-cell responses 
to TRAP using viral vectors.  
 
Method: 37 healthy malaria-naïve adults were vaccinated with either ChAd63-MVA 
expressing ME-TRAP and 3 doses of RTS,S/AS01B (Group 1, n=20) or 3 doses of 
RTS,S/AS01B alone (Group 2, n=17). CHMI was delivered by mosquito bites in 33 
vaccinated subjects at week 12 after first vaccination, and 6 unvaccinated controls. 
 
Results: No SUSAR or SAEs related to vaccination were reported. Protective vaccine 
efficacy was observed in 14/17 (82.4%) subjects in Group 1 and 12/16 (75%) subjects 
in Group 2. All control subjects were diagnosed with blood stage malaria. Both 
vaccination regimens were immunogenic. 14 protected subjects underwent repeat 
CHMI 6 months after initial CHMI; 7/8 (87.5%) Group 1 subjects and 5/6 (83.3%) 
Group 2 subjects remained protected. 
Conclusion: The high level of sterile efficacy observed in this trial is encouraging for 
further evaluation of combination approaches using these vaccine types. 
Clinicaltrials.gov Registration: NCT01883609 
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Introduction 
Malaria remains one of the leading causes of mortality globally,[1] and there is 
urgent need for a vaccine. The majority of deaths are in children less than 5 years 
old, with this age group accounting for approximately 306,000 deaths in 2015. The 
enormous economic and social consequences of malaria have been well 
documented.[2] Efforts to develop effective vaccines are complicated by the 
complex immunology of malaria infection, and no reliable natural model of complete 
immunity exists. Despite this, a small number of candidate vaccines have shown 
partial efficacy against experimental and natural human infection with the current 
leading vaccine being the recombinant protein in adjuvant, RTS,S/AS01. RTS,S targets 
the circumsporozoite protein (CS), which is expressed by the P. falciparum 
sporozoite at the pre-erythrocytic stage, and was the first subunit vaccine to show 
high rates of sterile efficacy, typically 50%, in controlled human malaria infection 
(CHMI) studies[3]. In a large African phase III trial, this vaccine has shown efficacy 
against clinical malaria of 55·8% (97·5% CI 50·6–60·4) in children aged 5–17 months 
and 31·3% (23·6–38·3) in infants aged 6–12 weeks over the first year after 
vaccination.[4, 5] Vaccine efficacy wanes over time, but can be enhanced by a fourth 
dose.[6] Analysis of the immunological correlates of efficacy of this vaccine suggest 
vaccine-induced antibodies targeting CS are the most important mediators of RTS,S-
induced protection against malaria,[3] although no antibody level threshold has 
been shown to be predictive of efficacy. The rate at which anti-CS antibodies wane is 
similar to the rate at which efficacy declines[7, 8] suggesting that anti-CS antibodies 
may also be associated with the duration of protection. A number of factors, 
 at Im
perial College of Science Technology and M
edicine on July 20, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
4 
 
including age at vaccination, HIV status and high baseline anti-CS antibody titers 
impact anti-CS antibody titers after vaccination with RTS,S.[9] 
The pre-erythrocytic stage of P. falciparum infection presents an attractive target for 
an efficacious human vaccine, as sufficient reduction in the number of viable 
merozoites reaching the blood from the liver will prevent parasitization of red blood 
cells and initiation of the symptomatic blood stage of infection.  Anti-CS antibodies 
can target sporozoites for destruction prior to hepatocyte invasion. As sporozoites 
travel from the skin to liver within minutes, it may be difficult for a vaccine to 
achieve complete protection against P. falciparum based solely on antibodies to 
sporozoites. The liver stage of infection provides a longer window of opportunity for 
cell-mediated immunity to recognize and destroy infected hepatocytes. ChAd63 ME-
TRAP and MVA ME-TRAP are viral vectored vaccines, and when administered in a 
prime-boost sequence at an eight-week interval is a leading candidate vaccine 
strategy targeting the liver stage of infection.[10] The chimpanzee adenovirus 
(ChAd63) and modified vaccinia Ankara (MVA) viral vectors deliver the recombinant 
ME-TRAP insert, which generates a potent cellular immune response against the 
liver-stage P. falciparum antigen, thrombospondin related adhesion protein (TRAP), 
of greater magnitude than the cellular response induced by RTS,S/AS01. This 
strategy showed durable partial efficacy in two Phase IIa sporozoite challenge trials 
in the UK[11, 12] using the 3D7 parasite as a challenge strain. The viral vector 
encoded P. falciparum TRAP allele is from the heterologous T9/96 strain and induced 
T cell responses correlate with efficacy.[11] Therefore these are effectively 
heterologous strain CHMI studies. Interestingly, a higher level of efficacy of 67% 
[95% CI 33-83] against P. falciparum infections detected by PCR was observed in a 
 at Im
perial College of Science Technology and M
edicine on July 20, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
5 
 
Phase IIb trial in Kenyan adults.[13] Again, T cells to TRAP peptides correlated with 
vaccine efficacy but the short duration of malaria transmission and follow-up at this 
trial site precluded analysis of the durability of vaccine-induced protection.[13] This 
heterologous prime-boost strategy showed potent cellular immunogenicity in adults 
in the UK,[11] as well as adults and infants in malaria endemic areas,[13-15] (Ewer et 
al submitted) and has an excellent track record of safety and tolerability in these 
populations. Analysis of the potential utility of combining anti-sporozoite and anti-
liver-stage vaccines have suggested a likely additive or synergistic effect[16] in 
keeping with findings from pre-clinical studies.[17, 18] 
In this phase I/IIa, open-label, CHMI study, we assessed the safety, immunogenicity 
and efficacy of a vaccine schedule combining these two distinct candidate vaccine 
types in a staggered immunization regimen: one that induces very high titer 
antibodies to CS using RTS,S/AS01B and the other inducing potent T cell responses to 
TRAP using viral vectors. 
 
Methods 
Participants 
Recruitment and vaccination was conducted at three UK sites, in Oxford, 
Southampton and London. The CHMI procedure was performed as previously 
described[19] using five infectious bites from P. falciparum 3D7-strain infected 
Anopheles stephensi mosquitoes at Imperial College, London. All subjects were 
infected with a single batch of mosquitoes at the initial CHMI, and with a second 
single batch at the repeat CHMI. Infected mosquitoes were supplied by the 
Department of Entomology, Walter Reed Army Institute of Research, Washington 
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DC, USA. Healthy, malaria-naïve males and non-pregnant females aged 18-45 years 
were invited to participate in the study. All volunteers gave written informed 
consent prior to participation, and the study was conducted according to the 
principles of the Declaration of Helsinki and in accordance with Good Clinical 
Practice (GCP). 
 
Ethical and Regulatory Approval 
Necessary approvals for the study were granted by the UK National Research Ethics 
Service, Committee South Central – Oxford A (Ref: 13/SC/0208), the Western 
Institution Review Board (Ref: 20130698) and the UK Medicines and Healthcare 
products Regulatory Agency (Ref: 21584/0317/001-0001). The trial was registered 
with ClinicalTrials.gov (Ref: NCT01883609). The Local Safety Committee provided 
safety oversight and GCP compliance was independently monitored externally by the 
Clinical Trials and Research Governance Team (CTRG) of the University of Oxford. 
 
Study Design 
This Phase IIa, open-label partially randomized challenge trial consisted of 4 cohorts. 
Allocation to study group occurred at screening based on subject preference. Any 
subjects without a preference were randomized to vaccine Group 1 or 2. Group 1 
(n=20) received 5 vaccinations (RTS,S/AS01B 50 µg at 0, 4 and 8 weeks, ChAd63 ME-
TRAP 5 x 1010 virus particles (vp) at 2 weeks, and MVA ME-TRAP 2 x 108 plaque 
forming units (pfu) at 10 weeks); Group 2 (n=20) received 3 vaccinations 
(RTS,S/AS01B  50 µg at 0, 4 and 8 weeks); Group 3 (n=6) received no vaccinations. All 
vaccinations were administered intramuscularly (IM) into the deltoid region of the 
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arm. In each volunteer, all RTS,S/AS01B injections were given in one arm, and all viral 
vector injections were given in the contralateral arm. All subjects underwent initial 
CHMI by mosquito bite at the same time (week 12 after first vaccination for 
vaccinated subjects). Following CHMI, a diagnosis of blood stage malaria infection 
was made in subjects with symptoms suggestive of malaria and positive thick film 
microscopy, or qPCR result >500 parasites/ml if either thick film was negative, or 
symptoms were absent. [12] Vaccinated subjects who had not developed blood 
stage malaria by day 21 after CHMI were deemed to exhibit sterile protection and 
were invited to undergo repeat CHMI 6 months later, for which an additional control 
group was recruited (Group 4). 
Further details of the study sites, inclusion/exclusion criteria, the vaccines, clinical 
follow-up, safety monitoring, malaria treatment and diagnosis, immunological and 
molecular methods, and statistics can be found in the supplementary material. 
 
Results 
Participants 
Eighty subjects were screened for eligibility and 48 subjects were identified as 
eligible.  Twenty subjects were allocated to group 1 to receive RTS,S/AS01B and viral 
vectors encoding ME-TRAP. Seventeen subjects were allocated to group 2 to receive 
RTS,S/AS01B only. Six unvaccinated controls were recruited to group 3 for the initial 
CHMI, and 5 subjects were allocated to group 4 for the repeat CHMI. Vaccinations 
took place between 2nd September 2013 and 13th November 2013. Prior to CHMI, 3 
subjects withdrew from group 1, and 1 subject withdrew from Group 2. There were 
no withdrawals due to safety concerns and no pre-defined study stopping or holding 
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rules were activated. CHMI was performed on the 25th and 26th of November 2013, 
and repeat CHMI on 13th May 2014 (Figure 1). 
 
Protective efficacy against CHMI 
A total of 39 subjects participated in the initial CHMI (17 subjects from Group 1, 16 
subjects from Group 2 and 6 subjects in Group 3),which was conducted over 2 days. 
Three subjects in Group 1 and 4 subjects in Group 2 were diagnosed with malaria 
before day 21 post-challenge, resulting in a sterile efficacy of 82.4% [95% CI 64-100] 
and 75% [95% CI 54-96] respectively (Figure 2). Median time to diagnosis was 14.5 
days in Group 1 and 13.25 days in Group 2. All 6 control subjects were diagnosed 
with malaria with a median time to diagnosis of 12.25 days (range 11-13, SD 0.7 
days). Both vaccine regimens demonstrated significantly reduced risk of malaria 
infection over controls in the per protocol analysis (Group 1 hazard ratio (HR) 0.065, 
p <0.0001; Group 2 HR 0.12, p <0.0001 for Group 2), but there was no significant 
difference in efficacy between vaccine regimen (HR 0.65, p 0.57). Eight Group 1 and 
6 Group 2 protected subjects agreed to undergo repeat CHMI. A single subject in 
each of Groups 1 and 2 were diagnosed with malaria at day 17 and day 14.5 
respectively, and all 5 control subjects developed malaria with a mean time to 
diagnosis of 12.4 days (Median 12.5, range 11.5-13.5, SD 0.8).  
 
Safety 
The safety profile of a 3 dose regimen of RTS,S/AS01B and of ChAd63-MVA ME-TRAP 
when given separately to malaria-naïve adults has been described previously,[3, 10-
12, 20] and a similar reactogenicity profile was observed after vaccination in this 
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study. The majority of adverse events (AEs) following vaccinations in both Group 1 
and Group 2 were mild in severity and self-limiting. There were no serious adverse 
events (SAEs) related to vaccination, and no Suspected, Unexpected Serious Adverse 
Reactions (SUSAR)s. Solicited and unsolicited AEs following vaccination are detailed 
in supplementary tables S1-S12.  
 
Humoral response to vaccination 
Anti-TRAP IgG antibodies (Abs) were measured in Group 1 subjects only (Figure 3), 
and geometric mean titers (GMTs) peaked on the day before challenge (C-1) at 947 
Elisa Units (EU) [95% CI 617-1455]. No association was detected between anti-TRAP 
IgG levels and efficacy (Spearman’s r=-0.25, p=0.3). Anti-CS Abs were measured at 
key time points in all vaccinated subjects. Serum anti-CS Abs peaked at C-1 in both 
vaccinated groups with peak GMT of 1733 EU [95% CI 1240-2422] and 1824 EU [95% 
CI 1330-2502] in groups 1 and 2 respectively. There was no significant difference in 
anti-CS Ab GMTs between group 1 and group 2 at C-1 (Mann-Whitney p>0.99). Anti-
CS Ab GMTs at C-1 were significantly higher in protected subjects than non-
protected subjects (Figure 3), (protected GMT 1985 EU [95% CI 1584-2487]; non-
protected GMT 1177 [95% CI 627-2209]; Mann-Whitney p=0.035). There was a 
correlation between Anti-CS Ab titer and parasite density at day 7.5, (Spearmans r=-
0.4, p=0.018). There was no significant difference in avidity of anti-CS Abs between 
protected and non-protected volunteers at any timepoint, however avidity 
significantly increased between Day 28 and C-1 in protected but not non-protected 
volunteers (p=0.001 and p>0.99 respectively, Wilcoxon matched-pairs test). Avidity 
also increased between Day 56 and C-1 in protected but not non-protected 
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volunteers (p<0.0001 and p=0.375 respectively, Wilcoxon matched-pairs test). In the 
protected vaccinated subjects who underwent repeat CHMI, avidity on the day 
before re-challenge (RC-1) remained significantly higher than at D28 (P=0.002, 
Mann-Whitney test).  
 
Cellular response to vaccination 
T-cell responses against ME-TRAP were measured in all Group 1 subjects by ex-vivo 
interferon-gamma (IFNγ) ELISPOT (Figure 4). Peak responses after ChAd63 ME-TRAP 
vaccination were detected 21 days later; GM 539 spot forming cells (SFC) per million 
peripheral blood mononuclear cells (PBMC) [95% CI 300-968]. Peak responses after 
MVA ME-TRAP vaccination were detected 7 days later; median 1520 SFC [inter-
quartile range (IQR) 699-3305]. T-cell responses against ME-TRAP were well 
maintained over time with a median of 464 SFC [IQR 231-933] 90 days after initial 
challenge, and 342 SFC [IQR 143-815] in participating subjects the day before repeat 
CHMI (RC-1).  
T-Cell responses against CS were measured in all vaccinated subjects by IFNγ ELISPOT 
(Figure 4). Responses peaked in Group 1 at C-1 (4 weeks after final dose of 
RTS,S/AS01B); median of 36 SFC [IQR 12-176]with responses at 12 SFC [IQR 12-70] in 
Group 2 at the same time point . No association between ELISPOT responses to TRAP 
or CS and vaccine efficacy was detected (Spearmans r=-0.01, p=0.98 and r=-0.001, 
p=0.0996 for TRAP and CS respectively).  
 Flow cytometry using Intracellular Cytokine Staining (ICS) was performed for CS and 
HBsAg at day 42 after first vaccination and C-1 using cryopreserved PBMC. In this 
assay, responses were described as the number of cells per million CD4+ or CD8+ T 
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cells expressing at least two markers from CD154 (CD40 ligand), IFNγ, IL-2 and TNFα 
(Figure 5A and B). CS-specific CD4+ T cell responses peaked at day 42 (two weeks 
after the second dose of RTS,S) in both groups and no significant differences were 
detected between Group 1 and 2 either at day 42 or C-1 (Figure 5C). CS-specific CD8+ 
T cell responses were not detected at any significant frequency.  A positive 
association was detected between the number of polyfunctional CD4+ T cells at D42 
and the level of anti-CS IgG in serum at C-1  (Figure 5D, Spearman’s r=0.4, p=0.03). 
Vaccination with RTS,S increased the frequency of HBS-specific CD4+ polyfunctional T 
cells in both groups at all time points after vaccination (Figure 5E and F). 
Flow cytometry was also performed on freshly isolated PBMC using CS peptides 
(Group 1 and 2 subjects) and ME-TRAP peptides (Group 1 subjects only) at C-1. 
Group 1 responses to TRAP T9/96 and 3D7 were comparable across all cytokines and 
CD107a (Kruskall-Wallis test with Dunn’s Correction P<0.0001), with all volunteers 
exhibiting at least one positive cytokine response to both TRAP strains (Figure 6A 
and B). A positive response was measured to CS in 15/17 (83%) group 1 volunteers 
compared to just 9/16 (56%) volunteers in group 2, with a significantly higher 
frequency of IFNγ-producing CD4+ T cells in group 1 (Figure 6C).   
By ex-vivo IFNγ ELISpot to CS peptides, a trend was observed towards higher 
responses in Group 1 compared to  Group 2 (Mann-Whitney test on combined 
groups p=0.0517); when assessed by peptide pool, a significant trend to higher 
responses was observed in pool 1 (Mann-Whitney test p=0.0380). This is likely due 
to CS epitope(s) present in the Multi-Epitope string of ChAd63 ME-TRAP and MVA 
ME-TRAP. Ex-vivo IFNγ data suggests that this epitope lies towards the N terminus of 
CS, as identified by a significantly higher Group 1 response to peptide pool 1. The 
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Multi Epitope string contains 2 epitopes present in pool 1: CD8 epitope cp26 
KPKDELDY; and CD4 epitope DPNANPN, as part of longer ME sequence 
DPNANPNNVDPNANPNV (Table 1). As the main differences in ICS IFNγ production 
were in the CD4+ T cell compartment, epitope DPNANPN could be responsible for 
the enhanced CS responses in group 1. This epitope is not present in RTS,S, so is 
solely induced by ChAd63.MVA ME-TRAP prime boost vaccination. 
 
 
Discussion 
Both RTS,S/AS01B and ChAd63-MVA encoding ME-TRAP have previously 
demonstrated partial efficacy in CHMI trials[3, 11, 12, 20] but this is the first study in 
which RTS,S/AS01B and ChAd63-MVA ME-TRAP have been given to subjects in the 
same vaccine regimen. In this study we have shown that administering these 
vaccines sequentially is safe, with no SUSARs, and no vaccine related SAEs. The 
reactogenicity profile observed in the subjects who received the combined vaccine 
regimen (Group 1) was similar to that observed when RTS,S/AS01B or ChAd63-MVA 
ME-TRAP were given alone in a malaria-naïve adult population. [3, 11, 12, 20]  
 
Furthermore, we have demonstrated that these vaccine candidates remain 
immunogenic when the regimens are combined. Anti-CS antibodies were not 
significantly different between Group 1 and Group 2 at C-1, and peak numbers of 
TRAP-specific T-Cells in Group 1 were similar to those observed with ChAd63-MVA 
ME-TRAP administered alone in a previous study.[11] Geometric mean titers of anti-
CS antibodies were significantly higher in protected subjects at C-1, but there was no 
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correlation between any TRAP or CS-specific T cell assays or TRAP-specific IgG and 
protection. 
 
In this study we observed a high level of protective efficacy in both vaccine arms. A 
higher proportion of subjects in Group 1 remained protected following CHMI than in 
Group 2 (82.4% vs. 75% respectively), though this difference was not statistically 
significant (p=0.57). This high level of vaccine efficacy was also seen to be durable at 
6 months with 87.5% and 83.3% of initially protected subjects who underwent 
repeat CHMI remaining protected in Groups 1 and 2 respectively. In addition, a 
higher proportion of subjects in Group 1 reached the secondary efficacy endpoints of 
delay to malaria diagnosis and delay to PCR parasitemia compared with Group 2. The 
trends observed in this study for initial challenge, rechallenge and effects on the pre-
patent period are encouraging for further evaluation of the Group 1 regimen, but 
the numbers in this study are small, and the differences observed not statistically 
significant. In 2013, a CHMI study of the cryopreserved whole sporozoite (PfSPZ) 
vaccine reported sterile efficacy of 100% in the high dose regimen consisting of 5 
doses of 1.35 x 105 parasites.[21] However, the vaccinee numbers in the high dose 
group were small (n=6) and only 5/6 (83.3%) of the unvaccinated controls developed 
blood stage infection, raising concerns over the infectivity of the parasites used in 
that CHMI. The results observed in the trial we present in this article, therefore 
appear to represent the highest published sterile vaccine efficacy in any CHMI study 
in which all the control subjects were infected. 
The level of protective efficacy observed in the RTS,S/AS01B alone group (75%) is 
higher than has been reported in most prior CHMI studies of this vaccine regimen.[3, 
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20]. The mean time to patency in the control group of 12.2 days indicates that this 
was not an unusually weak challenge, and the vaccination and CHMI methodology 
used in this trial are largely comparable to other CHMI studies of this dosing 
schedule of RTS,S/AS01.[3] Practical limitations on study size are a factor for both 
this study and prior CHMI studies of RTS,S, resulting in a relatively small historical 
dataset. In light of this, it is possible that the higher efficacy seen in the RTS,S alone 
group in this trial is a chance finding, due in part to small numbers, or that further 
CHMI studies of RTS,S/AS01 in malaria-naïve subjects, including further evaluation of 
differing dosing regimens and schedules would further clarify the efficacy of the 
vaccine in this setting. The study was designed to have 84% power to detect a 
significant (p <0.05) increase in sterile efficacy in Group 1 to 90%, and with 69% 
power to detect a significant increase to 85% compared to Group 2. This power 
calculation assumed an expected 50% sterile efficacy in Group 2.[3] The increase in 
efficacy to 82.4% in Group 1 from 75% in Group 2 observed in this trial was not 
statistically significant (p=0.69), but power to detect a statistically significant 
improvement was very limited. Practical limitations of CHMI trials makes conducting 
large studies difficult, and designing future studies with sufficient power would be 
complicated, assuming efficacy of 75% in an RTS,S/AS01B alone group. One 
alternative approach is to wait longer post immunization to allow vaccine efficacy to 
wane and thereby provide greater power to detect additive or synergist effects of 
combination vaccines. Further consideration of this issue, and of the practical 
limitations of CHMI studies with challenge at 3 to 4 weeks post last vaccination in 
future trial designs is warranted. 
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We undertook a re-challenge of protected subjects at 6 months after the initial 
CHMI, 7/8 (87.5%) Group 1 subjects and 5/6 (83.3%) Group 2 subjects remained 
protected. By simply calculating the product of the percentage efficacies in the two 
CHMIs one can estimate vaccine efficacy at six to seven months after the 
immunizations as a measure of durable sterile protection. For Group 1 this is 72% 
(14/17 x 7/8 x 100%) and for Group 2, 62.5% (12/16 x 5/6 x 100%). Again the durable 
protection rate at this time point in Group 2 appears higher than in previous re-
challenge trials with RTS,S/AS01B administered three times[3] and the Group 1 
protection rate is even higher. This durability at six months is also encouraging for 
continued investigation of combination vaccine approaches and supports the 
consideration of delayed CHMI as an approach to evaluating improvements in 
efficacy provided by vaccines that confer substantial short term efficacy. 
In this trial, we present data from a combined vaccine regimen in which subjects 
received a total of five vaccinations over a 10-week period. A priority for future 
studies should be to evaluate the effect of simplifying the vaccination schedule. A 
study evaluating the concomitant administration of RTS,S with viral vectors 
expressing ME-TRAP, thereby reducing the total number of vaccinations in a more 
practical schedule for potential deployment is currently underway.  
These results are encouraging for further evaluation of malaria vaccine regimens 
that combine viral vectors with protein subunits, and also vaccine regimens that 
target multiple stages of the malaria parasite life cycle. 
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FIGURE LEGENDS 
Figure 1: Flow of study design and volunteer recruitment. Twenty-seven subjects 
were excluded according to inclusion/exclusion criteria. Three subjects withdrew 
consent after screening, but before enrolment. Two subjects were deemed eligible 
as control subjects but only after Group 3 enrolment was complete. They were kept 
as backup subject in case of last minute withdrawals from Group 3, but never 
underwent CHMI. 17 subjects expressed a preference as to which vaccine group to 
be allocated to, and were assigned accordingly. 20 subjects expressed no preference 
for vaccine group allocation, and were therefore randomized to group by the study 
statistician. ChAd63, Chimpanzee adenovirus serotype 63; MVA, Modified vaccinia 
virus Ankara; ME-TRAP, multiple-epitope thrombospondin-related adhesion protein; 
CHMI, Controlled human malaria infection.  
 
Figure 2: Efficacy of RTS,S/AS01B with ChAd63-MVA ME-TRAP immunization and 
RTS,S/AS01B immunization alone following Plasmodium falciparum 3D7 sporozoite 
challenge. Kaplan–Meier survival analyses. Log-rank test for significance. A, Kaplan–
Meier survival analysis of time to treatment following initial CHMI. Mean time to 
diagnosis was 12.2 (± 0.7) days for unvaccinated controls. Seventeen out of 17 
subjects in Group 1 (100%) and 14 out of 16 subjects in Group 2 (87.5%) were 
undiagnosed by day 21, or diagnosed after the control mean +2 SD. B, Kaplan–Meier 
survival analysis of time to first sample with >20 parasites/mL detected by 
quantitative polymerase chain reaction (qPCR). Mean time to endpoint was 7.4 (± 
0.7) days for unvaccinated controls. Sixteen out of 17 subjects in Group 1 (94.1%) 
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and 15 out of 16 subjects in Group 2 (93.8%) did not reach this endpoint, or did so 
after the control mean +2 SD. C, Kaplan–Meier survival analysis of time to first 
sample with >500 parasites/mL detected by qPCR. Mean time to endpoint was 9.8 
(±0.8) days for unvaccinated controls. Seventeen out of 17 subjects in Group 1 
(100%) and 15 out of 16 subjects in Group 2 (93.8%) did not reach this endpoint, or 
did so after the control mean +2 SD. D, Kaplan–Meier survival analysis of time to 
treatment following repeat CHMI in protected subjects. Abbreviations: CHMI, 
controlled human malaria infection; controls, unvaccinated volunteers undergoing 
CHMI; ME-TRAP, multiple epitope–thrombospondin related adhesion protein. 
 
Figure 3: Antibody responses to vaccination measured by enzyme-linked 
immunosorbent assay (ELISA). A, Anti-thrombospondin adhesion protein (TRAP) 
immunoglobulin G (IgG) antibody responses after vaccination with RTS,S/AS01B plus 
ChAd63-MVA ME-TRAP (Group 1 subjects only). Lines represent group medians. B, 
Anti-circumsporozoite protein (CS) immunoglobulin G (IgG) antibody responses after 
vaccination with RTS,S/AS01B plus ChAd63-MVA ME-TRAP (Group 1; blue) or RTS,S 
alone (Group 2; black). Line represents group median. C, Comparison of Anti-CS IgG 
antibody responses between Group 1 (Blue) and Group 2 (Black) as measured on the 
day before CHMI (C-1). No significant difference (NSD) P>0.999 by Mann-Whitney 
analysis. Comparison of anti-CS IgG antibody responses in volunteers that were 
sterilely protected or not. Lines represent geometric mean. D, Correlation between 
anti-CS IgG titres at C-1 and parasite density at day 7 post-challenge. Spearman’s r=-
0.4, p=0.018. E, Avidity of total IgG against the NANP repeat region of CSP. 
Significant increase in avidity between D28 and C-1 in protected, but not non-
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protected volunteers. P=0.001, Wilcoxon matched-pairs test. Avidity of total IgG 
remained significantly higher at time of 2nd CHMI (RC-1), compared to D28. P=0.002, 
Mann-Whitney test. Lines represent geometric mean. Abbreviations: ChAd63, simian 
adenovirus 63; CHMI, controlled human malaria infection; EU, ELISA units; MVA, 
modified vaccinia virus Ankara; C+, value denotes elapsed time after CHMI in days.  
 
Figure 4: Antigen-specific T-cell responses to vaccination measured by IFNγ 
ELISPOT. A, Median T-cell responses to ME-TRAP. B, Median T cell responses to CSP 
peptide pools are shown for Group 1 (RTS,S/AS01 and ME-TRAP, blue line) and 
Group 2 (RTS,S/AS01, black line). 
 
Figure 5: T cell responses by flow cytometry on cryopreserved peripheral blood 
mononuclear cells pre- and post-vaccination for CSP and Hepatitis B surface antigen 
(HBS). Polypositive indicates number of cells per million expressing 2 or more of the 
following markers; CD154 (CD40 ligand), IFNγ, Il-2 and TNFα. A and B, Number of 
CSP-specific polypositive CD4+ or CD8+ T cells per million in Group 1 and 2 
respectively. C, Comparison of CD4+ polypositive T cells at peak time point post 
vaccination (day 42) and day before CHMI (C-1) for Group 1 (G1) and 2 (G2). D, 
Correlation between peak CSP-specific CD4+  polypositive frequency and anti-CS IgG 
level at C-1 (r=0.4, p=0.03, Spearman’s test). E and F, Number of HBS-specific 
polypositive CD4+ or CD8+ T cells per million in Group 1 and 2 respectively.  
Figure 6: Intracellular cytokine staining of PBMC one day prior to CHMI (27 days post 
final RTS,S vaccination and 13 days post MVA ME-TRAP vaccination), showing 
 at Im
perial College of Science Technology and M
edicine on July 20, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
24 
 
CD107a expression frequency and frequencies of cytokine-secreting cells, as a 
percentage frequency of parent CD4+ and CD8+ T cells. Geometric mean of each 
response is shown in response to stimulation with A) TRAP T9/96 peptides 
(homologous to vaccine insert) by Group 1, B) TRAP 3D7 peptides (homologous to 
CHMI challenge strain) by Group 1 and C) CS peptides by Group 1 and 2.  D) Ex-vivo 
IFN- ELISpot responses of Group 1 and 2 volunteers to CS peptides split into 3 
peptide pools and a combined pool, with background subtracted. Dotted line shows 
the median background ELISpot response, setting the positive response threshold.    
N=17 for group 1 and n=16 for group 2.  Data points represent individual volunteers. 
 
Table 1: Comparison of peptide sequences present in Multi-Epitope string of ME-
TRAP and the T cell region of RTS,S (Lalvani et al 1999). 
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